Melanoma Research Institute of Excellence
Contact
Name:
Mitchell Berkowitz
Position:
Program Manager
Organization:
Melanoma Research Institute of Excellence
Contact Number(s):
Contact
Name:
Shingo Sato
Position:
- Associate Program Manager
- Director of Database Design and Utilization
Organization:
Melanoma Research Institute of Excellence
Email:
Shingo.Sato@jefferson.edu
Contact Number(s):
2024 Publications
- A rat-based preclinical platform facilitating transcatheter hepatic arterial infusion in immunodeficient rats with liver xenografts of patient-derived pancreatic ductal adenocarcinoma
- Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
- Lineage commitment pathways epigenetically oppose oncogenic Gαq/11-YAP signaling in dormant disseminated uveal melanoma
- Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
- Overall Survival From Tebentafusp Versus Nivolumab Plus Ipilimumab in First Line Metastatic Uveal Melanoma: A Propensity Score Weighted Analysis
- Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress
- SOX10 loss sensitizes melanoma cells to cytokine-mediated inflammatory cell death.
2023 Publications
- A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
- Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy
- Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth
- ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM)
- Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
- Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas
- Hepatic Arterial Infusion of the Class C TLR9 Agonist SD-101 in Pressure Enabled Regional Immuno-Oncology (PERIO) Phase 1 Trials for Liver Tumors
- High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma
- HLA discordance between blood and tumor: A treatment conundrum?
- IGFR1 inhibition enhances the therapeutic effects of Gq/11 inhibition in metastatic uveal melanoma progression
- Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma
- MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping
- Targeting upregulated cIAP2 in SOX10-deficient drug tolerant melanoma.
- Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
- The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma
- Three- Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
- Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
2022 Publications
- A circulating, surrogate-systemic biomarker correlates with anti-tumor benefit on LNS8801 therapy
- A genome-wide screen identifies PDPK1 as a target to enhance the efficacy of MEK1/2 inhibitors in NRAS mutant melanoma
- A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma
- A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma
- Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662)
- Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases
- Clinical and molecular response to tebentafusp in previously-treated patients with metastatic uveal melanoma: a phase 2 trial
- Conditional survival of uveal melanoma using The Cancer Genome Atlas (TCGA) classification (Simplified Version) in 1001 cases.
- Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
- Improved uveal melanoma copy number subtypes including an ultra–high-risk group.
- Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma
- Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients
- Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors
- Phase 1b study of the novel first-in- class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update
- Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma
- Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: The final analysis of cohort 1
- Raptinal induces GSDME-dependent pyroptosis in naïve and therapy-resistant melanoma
- Review of bi-specific therapies in uveal melanoma
- Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma
- The AMP-dependent kinase pathway is up-regulated in BAP1 mutant uveal melanoma Pigment Cell Melanoma Res
- The future of targeted kinase inhibitors in melanoma
- Treatment of Metastatic Melanoma in the Elderly
- Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)